Education
About Us
Working with TipRanks
Follow Us
Immunocore Holdings (IMCR)
NASDAQ:IMCR
IMCR Stock Chart & Stats
$36.19
-$0.07(-0.21%)
At close: 4:00 PM EST
$36.19
-$0.07(-0.21%)
Day’s Range― - ―
52-Week Range$23.15 - $40.71
Previous CloseN/A
Volume28.13K
Average Volume (3M)298.58K
Market Cap
$1.85B
Enterprise Value$1.37B
Total Cash (Recent Filing)$892.35M
Total Debt (Recent Filing)$43.27M
Price to Earnings (P/E)―
Beta0.76
Next Earnings
Mar 04, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding50,530,420
10 Day Avg. Volume280,678
30 Day Avg. Volume298,584
Financial Highlights & Ratios
PEG Ratio2.97
Price to Book (P/B)4.09
Price to Sales (P/S)4.75
P/FCF Ratio70.60
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue3.62
Enterprise Value/Gross Profit3.65
Enterprise Value/Ebitda-181.72
Forecast
1Y Price Target
$65.25Price Target Upside80.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-0.36
Revenue Forecast (FY)$402.89M
Bulls Say, Bears Say
Bulls Say
Financial PerformanceImmunocore advanced multiple programs maintaining strong financial flexibility with $892 million in liquidity.
Market ExpansionCommercial momentum in mUM continues to strengthen, driven by expanding real-world treatment duration and accelerating demand in Europe.
Product PerformanceKIMMTRAK remains the standard of care for HLA-A*02:01–positive mUM, now approved in 39 countries and launched in 28, and continues to drive sustainable revenue growth through treatment duration and geographic expansion.
Bears Say
Cost ImpactKimmtrak is manufactured in Europe and has potential exposure to COGS impact from evolving tariff policy, which could begin to manifest once existing US stock is depleted.
Market CompetitionKimmtrak faces emergent competitive pressure from IDYA’s darovasertib + crizotinib, which may serve as negative catalysts on potential for the regimen to erode Kimmtrak’s market share in HLA-A2+ patients.
Revenue EstimatesThe 2025 Kimmtrak revenue estimate was slightly decreased.
Immunocore Holdings News
IMCR FAQ
What was Immunocore Holdings’s price range in the past 12 months?
Immunocore Holdings lowest stock price was $23.15 and its highest was $40.71 in the past 12 months.
What is Immunocore Holdings’s market cap?
Immunocore Holdings’s market cap is $1.85B.
When is Immunocore Holdings’s upcoming earnings report date?
Immunocore Holdings’s upcoming earnings report date is Mar 04, 2026 which is in 68 days.
How were Immunocore Holdings’s earnings last quarter?
Immunocore Holdings released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$0.232 by $0.232.
Is Immunocore Holdings overvalued?
According to Wall Street analysts Immunocore Holdings’s price is currently Undervalued.
Does Immunocore Holdings pay dividends?
Immunocore Holdings does not currently pay dividends.
What is Immunocore Holdings’s EPS estimate?
Immunocore Holdings’s EPS estimate is -0.19.
How many shares outstanding does Immunocore Holdings have?
Immunocore Holdings has 50,530,420 shares outstanding.
What happened to Immunocore Holdings’s price movement after its last earnings report?
Immunocore Holdings reported an EPS of $0 in its last earnings report, beating expectations of -$0.232. Following the earnings report the stock price went up 2.597%.
Which hedge fund is a major shareholder of Immunocore Holdings?
Currently, no hedge funds are holding shares in IMCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunocore Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$65.25 (80.30% Upside)
$65.25 (80.30% Upside)
Blogger Sentiment
Bullish
IMCR Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 50.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.59%
12-Months-Change
Fundamentals
Return on Equity
-7.52%
Trailing 12-Months
Asset Growth
1.65%
Trailing 12-Months
Company Description
Immunocore Holdings
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
IMCR Company Deck
IMCR Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call showcased strong financial performance with significant growth in KIMMTRAK sales and global expansion. The company is advancing its pipeline with multiple Phase III trials and early-stage programs. While operating expenses have increased, the overall financial health remains robust, and growth is expected to moderate. The highlights significantly outweigh the lowlights, indicating a positive sentiment.View all IMCR earnings summariesIMCR Stock 12 Month Forecast
Average Price Target
$65.25
▲(80.30% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---